middle.news
How Will EBR Systems Capitalize on FDA Approval of Leadless WiSE CRT Amid Financial Strain?
2:35am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
How Will EBR Systems Capitalize on FDA Approval of Leadless WiSE CRT Amid Financial Strain?
2:35am on Monday 2nd of June, 2025 AEST
Key Points
FDA approval granted for WiSE CRT System, world’s first leadless left ventricular pacing device
Accepted into CMS’s TCET pathway and proposed for maximum NTAP reimbursement
Signed 11-year lease for expanded 51,000 sq. ft. manufacturing facility in Santa Clara
Reported Q1 2025 net loss of $10.6 million with $52.8 million in cash and securities
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
EBR SYSTEMS (ASX:EBR)
OPEN ARTICLE